New Alzheimer’s Drugs Extend Independent Living by Months

In recent years, the FDA approved two breakthrough Alzheimer’s therapies: lecanemab and donanemab. Both antibody treatments target amyloid plaques in the brain, which contribute to cognitive decline. Though the medications showed promise in clinical trials by slowing disease progression, patients and their families struggled to grasp how these findings applied to real-life outcomes including independent living.

Transforming Clinical Data into Actionable Information

Researchers at Washington University in St. Louis have taken a new approach to explain the benefits of these therapies. By analyzing data from clinical trials and the natural history of Alzheimer’s, they calculated how long patients could expect to live independently if treated. Their findings, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, offer a more relatable way of understanding the drugs’ impact.

Understanding Independent Living with Alzheimer’s

The researchers found that patients starting treatment with very mild symptoms could expect up to 10 additional months of independent living with lecanemab or 8 months with donanemab. For patients with more moderate symptoms, the expected increase in self-care ability ranged from 19 to 26 months, depending on the drug used.

The Patient Perspective: More Than Cognitive Decline

Senior author Sarah Hartz, MD, PhD, emphasized the importance of presenting drug effects in a manner that resonates with patients. “What people want to know is how long they will be able to live independently, not just abstract changes in cognitive decline,” she said.

Navigating Treatment Decisions

While both drugs can slow cognitive decline, they do not halt disease progression. Treatment carries risks, including brain swelling and bleeding, which are usually mild but can occasionally be severe. Therefore, patients must weigh the potential benefits against these risks and the high cost of treatment, including biweekly or monthly infusions.

Conclusion

This study’s goal is not to advocate for or against these treatments but rather to provide crucial information for patients and caregivers. It helps them make informed decisions based on their priorities, risk tolerance, and the real-world impact on their independence.

More Information:Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer disease, Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2025). DOI: 10.1002/trc2.70033